Navigation Links
Reata Pharmaceuticals to Present at 30th Annual J.P. Morgan Healthcare Conference
Date:1/6/2012

IRVING, Texas, Jan. 6, 2012 /PRNewswire/ -- Reata Pharmaceuticals, Inc. today announced that Warren Huff, President and CEO, will present a company overview at the 30th Annual J.P. Morgan Healthcare Conference.  The presentation will take place on Tuesday, January 10, at 10:00 a.m. PST in the Elizabethan C/D Room at the Westin St. Francis Hotel in San Francisco, CA.

Mr. Huff's presentation will include an update on the development of bardoxolone methyl, a first-in-class antioxidant inflammation modulator (AIM) for patients with advanced chronic kidney disease.  He will discuss data from the recent Phase 2b BEAM trial, which was published in the New England Journal of Medicine, as well as the status of the ongoing Phase 3 BEACON trial, a global study of 2,000 patients with advanced chronic kidney disease and type 2 diabetes. 

In addition, Mr. Huff will provide an overview of the company's recently announced agreement with Abbott to jointly develop and commercialize Reata's portfolio of new AIMs worldwide.  The collaboration includes a large number of molecules in a broad range of therapeutic areas.  This is the company's second partnership with Abbott.

About Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. is the leader in discovering and developing novel, oral anti-inflammatory drugs that activate Nrf2, the primary regulator of cellular antioxidant and detoxification enzymes, and suppress NFkB, the primary regulator of inflammatory genes. Reata is developing these compounds – called antioxidant inflammation modulators (AIMs) – with the goal of one day making them available to patients suffering from a broad range of diseases associated with inflammation and oxidative stress. Reata plans to build a stand-alone, fully integrated pharmaceutical company with a worldwide medical, commercial, and regulatory presence. For more information, please visit www.reatapharma.com.

Reata Contacts

Media: Matt Middleman or David Schull, matt.middleman@russopartnersllc.com, 212-845-4272; david.schull@russopartnersllc.com, 212-845-4271

Investors: Alan Roemer, aroemer@troutgroup.com, 1-646-378-2945


'/>"/>
SOURCE Reata Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Scripps Research team discovers treatable mechanism responsible for often deadly response to flu
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
4. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
5. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
6. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
7. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
8. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
9. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
10. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
11. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... IL (PRWEB) , ... September 19, 2017 , ... The ... environments and time. The pocket testers even stand upright with a new cap design ... lab or out in the field who need to test water quality. , The ...
(Date:9/19/2017)... Sept. 19, 2017 ValGenesis Inc., the global ... pleased to announce the strategic partnership with VTI Life ... with validation services using the latest technology available in ... provide clients with efficient and cost-effective validation services using ... for the ValGenesis VLMS system. ...
(Date:9/19/2017)... Sunnyvale, California (PRWEB) , ... September 19, 2017 ... ... cell biology technologies, today announced a partnership with Cytena GmbH to launch the ... technology and real-time image analysis to isolate single cells and provide visual documentation ...
(Date:9/19/2017)... , ... September 19, 2017 , ... ... technologies for surgical applications, announced today that two new patents have been allowed ... Albert, MD, Co-Founder of Band-LOK, said, “We continue to explore additional clinically-relevant designs ...
Breaking Biology Technology:
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, Inc. ... technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate governance ... Gino ... we look forward to their guidance and benefiting from their ...
(Date:4/5/2017)... , April 5, 2017 Today ... announcing that the server component of the HYPR platform ... for providing the end-to-end security architecture that empowers biometric ... HYPR has already secured over 15 million users ... including manufacturers of connected home product suites and physical ...
Breaking Biology News(10 mins):